Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board

Description

This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.

Conditions

Incurable Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.

Feasibility of Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board in Cancer Patients

Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board

Condition
Incurable Disease
Intervention / Treatment

-

Contacts and Locations

Tampa

Moffitt Cancer Center, Tampa, Florida, United States, 33613

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
  • * Participant must have a life expectancy greater than 3 months
  • * Participant must have an ECOG performance status 0-2
  • * Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB
  • * Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling.
  • * None

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

H. Lee Moffitt Cancer Center and Research Institute,

Jingsong Zhang, MD, PRINCIPAL_INVESTIGATOR, Moffitt Cancer Center

Study Record Dates

2028-03